Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR) (Q62660503)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 March 2011

Language	Label	Description	Also known as
English	Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR)	scientific article published on 10 March 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

Alessandro Sciarra

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Alessandro Gentilucci

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Vincenzo Gentile

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Valeria Panebianco

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Stefano Salciccia

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Danilo Lisi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Andrea Alfarone

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Ulderico Parente

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Susanna Cattarino

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Roberto Passariello

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

10 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

614-619

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Functional magnetic resonance imaging in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Role of Dynamic Contrast-Enhanced Magnetic Resonance (MR) Imaging and Proton MR Spectroscopic Imaging in the Detection of Local Recurrence after Radical Prostatectomy for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

3D MR spectroscopic imaging in the evaluation of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Magnetic resonance spectroscopy in patients with locally confined prostate cancer: association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

[EAU guidelines on prostate cancer].

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Testosterone stimulates the biosynthesis of m-aconitase and citrate oxidation in prostate epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Pathological changes in prostate lesions after androgen manipulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Proton MR spectroscopy of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.09.006

7 January 2021

Identifiers

10.1016/J.UROLONC.2010.09.006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21396849%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q62660503&oldid=1966870373"